New hope in PARP inhibitors
Loading player...
Dr Trudy Smith shares how advancements in genetics and targeted therapies, such as PARP inhibitors, are reshaping the landscape of ovarian cancer.
This article is sponsored by AstraZeneca in the interest of education, awareness, and support. The content and opinions expressed are entirely the healthcare expert’s own work and not influenced by AstraZeneca in any way.
Dr Trudy Smith is a gynaecology oncologist at Wits Donald Gordon Medical Centre and a senior lecturer at the University of Witwatersrand. She has a keen interest in teaching postgraduates and undergraduates.
This article is sponsored by AstraZeneca in the interest of education, awareness, and support. The content and opinions expressed are entirely the healthcare expert’s own work and not influenced by AstraZeneca in any way.
Dr Trudy Smith is a gynaecology oncologist at Wits Donald Gordon Medical Centre and a senior lecturer at the University of Witwatersrand. She has a keen interest in teaching postgraduates and undergraduates.
